Parkinson’s disease is a progressive neurodegenerative condition characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, and bradykinesia, as well as a range of non-motor effects. While current pharmacological treatments can manage symptoms, there is ongoing scientific interest in compounds that may help slow neurodegeneration or support neuronal health. Lion’s mane mushroom (Hericium erinaceus) has drawn attention in this context, largely because of its documented effects on nerve growth factor (NGF) synthesis and neuroprotective bioactivity. The research is early-stage, and most findings come from preclinical models, but the mechanistic rationale is considered scientifically credible by researchers in the field.
The Compounds Behind the Interest
Lion’s mane contains two classes of bioactive compounds that have attracted the most scientific attention: hericenones, found primarily in the fruiting body, and erinacines, found in the mycelium. Of these, erinacine A has been studied most thoroughly for its neurological effects.
Erinacine A is a cyathane diterpenoid that is able to cross the blood-brain barrier, a property that distinguishes it from many other bioactive compounds. Research indicates it stimulates NGF synthesis in the central nervous system, which plays a role in the survival, differentiation, and maintenance of neurons. A 2026 review examining recent advances in erinacine A preparation and biological activity noted its significant therapeutic promise for neurodegenerative disorders including Parkinson’s disease, primarily through its ability to stimulate NGF synthesis in brain tissue.[1] The authors also noted that the clinical applicability of erinacine A remains constrained by challenges related to bioavailability and extraction, areas that ongoing research is working to address.
Preclinical Findings in Parkinson’s Models
Much of the existing evidence related to Parkinson’s disease comes from animal and cell-based studies. These models typically involve inducing dopaminergic neuron loss using neurotoxins such as MPTP or 6-OHDA, then assessing whether lion’s mane extracts or isolated compounds alter the course of that damage.
In these preclinical contexts, lion’s mane extracts have been associated with reduced oxidative stress, modulated inflammatory signaling, and in some models, partial preservation of dopaminergic neurons. A 2023 review of Hericium erinaceus in neurodegenerative diseases examined the breadth of bench research and noted that while results in animal models are encouraging, the translation to human clinical outcomes remains unconfirmed.[2] The review also highlighted a need for randomized clinical trials specifically targeting Parkinson’s disease before conclusions about therapeutic utility can be drawn.
Oxidative Stress and Mitochondrial Function
Oxidative stress is a key driver of dopaminergic neuron degeneration in Parkinson’s disease. Reactive oxygen species accumulate in affected neurons, contributing to cell death. Preclinical studies have examined whether lion’s mane polyphenols and polysaccharides can modulate this process. A 2025 narrative review of Hericium erinaceus as a neuroprotective fungus summarized its antioxidant and anti-inflammatory properties, noting that extracts may support mitochondrial resilience and reduce markers of neuronal oxidative damage in experimental settings.[3] These mechanisms are considered relevant to Parkinson’s pathology, though direct clinical evidence is still limited.
Neuroinflammation
Chronic neuroinflammation, mediated in part by microglial activation, is also implicated in the progression of Parkinson’s disease. Laboratory findings suggest that lion’s mane extracts may downregulate certain pro-inflammatory cytokines and reduce microglial activation in neural tissue. However, it should be emphasized that these observations are drawn from in vitro and animal experiments and have not been replicated in clinical populations with Parkinson’s disease.
NGF Stimulation and Dopaminergic Neuron Survival
The relationship between NGF and dopaminergic neuron health is an area of active inquiry. NGF is primarily associated with cholinergic neuron maintenance, but broader neurotrophic signaling, including brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), is relevant to dopamine-producing cell survival. Some researchers have proposed that compounds stimulating NGF may indirectly support a neurochemical environment more favorable to dopaminergic neuron health, though this connection is speculative in the context of Parkinson’s disease specifically.
The broader neurodegenerative research on lion’s mane, particularly studies focused on Alzheimer’s disease, provides some mechanistic context. For a summary of that evidence, see our related article: Lion’s Mane and Alzheimer’s: What Science Says So Far.
What the Research Does Not Yet Show
It is important to be direct about the current state of evidence. As of 2026, there are no published randomized controlled trials specifically examining lion’s mane supplementation in individuals diagnosed with Parkinson’s disease. The mechanistic rationale for further investigation is scientifically grounded, but clinical efficacy and safety in this population have not been established.
This distinction matters: preclinical data showing neuroprotective effects in animal models does not reliably predict clinical benefit in humans. The history of neurodegenerative disease research includes many compounds that appeared effective in animal models but failed to demonstrate benefit in human trials. Lion’s mane may or may not follow a different trajectory; the evidence base does not yet allow for a firm conclusion either way.
Dosing and Safety Considerations
Lion’s mane has a well-documented safety profile in the studies that have been conducted, generally involving healthy adults or individuals with mild cognitive impairment. Adverse effects reported in published trials have been minor. However, individuals with Parkinson’s disease are often managing complex medication regimens, including levodopa and dopamine agonists, and no studies have evaluated potential interactions between lion’s mane compounds and these medications.
Anyone considering lion’s mane supplementation alongside existing Parkinson’s disease treatment should discuss this with a neurologist or treating physician before proceeding. The gap between promising preclinical findings and clinically validated recommendations is significant.
Where the Research Needs to Go
Researchers have called for well-designed clinical trials exploring Hericium erinaceus extracts, particularly erinacine A-rich mycelium preparations, in Parkinson’s populations. Such trials would need to address bioavailability, dosing standardization, duration of intervention, and validated outcome measures for both motor and non-motor symptoms. Some researchers have also proposed that functional mushrooms may be better studied as adjunctive rather than standalone interventions, a framing that may better reflect how they are actually used in practice.
The scientific interest in lion’s mane for neurodegeneration is legitimate and growing, but it remains an area of early investigation. What current research suggests is a plausible biological basis for further study, not a clinical recommendation.
References
- Wang J, et al. Recent Advances in Erinacine A: Preparation, Biological Activities, and Biosynthetic Pathway. Molecules. 2026;31(2):219. PMID: 41599268
- Brandalise F, et al. Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond. J Fungi (Basel). 2023;9(5):551. PMID: 37233262
- Contato AG, Conte-Junior CA. Lion’s Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential. Nutrients. 2025;17(8):1307. PMID: 40284172
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Lion’s mane mushroom supplements have not been approved by the FDA to diagnose, treat, cure, or prevent any disease, including Parkinson’s disease. Consult a qualified healthcare provider before making any changes to your health regimen.
